Last updated: February 15, 2026
What Is the Current Market for NDC 70010-0668?
NDC 70010-0668 is a drug marketed under the brand name Xyrem (sodium oxybate). Approved by the FDA in 2002, it is indicated for narcolepsy and cataplexy. Its primary therapeutic utility has kept it in a niche medical segment, with an estimated global sales reaching approximately $700 million in 2022, according to IQVIA data.
Xyrem's market is concentrated primarily in the United States, with a gradual expansion into select European markets. The drug is supplied via a restricted distribution system (Xyrem REMS Program), which controls supply due to its high potential for abuse, classified as a Schedule III controlled substance.
What Are the Market Drivers and Constraints?
Market Drivers:
-
Growing prevalence of narcolepsy: The National Sleep Foundation reports an estimated prevalence of 0.05% to 0.1% for narcolepsy in the U.S., translating into roughly 150,000 diagnosed cases.
-
Increasing recognition of cataplexy: Many patients with narcolepsy experience cataplexy, which Xyrem effectively manages.
-
Limited therapeutic alternatives: While other medications exist, few provide the same level of efficacy for both narcolepsy and cataplexy management.
Market Constraints:
-
Stringent REMS program: Limits the patient pool due to strict distribution controls.
-
Pricing and reimbursement: The drug's high cost (list price approx. $30,000 annually) limits access, especially outside the U.S.
-
Safety profile: Potential for abuse and adverse effects restricts broader application and prescriber receptiveness.
What Are Current Price Structures?
In the U.S., the average wholesale price (AWP) for Xyrem is approximately $30,000 per year per patient. Manufacturers and payers negotiate substantial discounts and rebates, leading to net prices between $10,000 and $20,000 annually, depending on insurance coverage and patient assistance programs.
European pricing varies, generally ranging from $15,000 to $25,000 annually, affected by national healthcare policies.
What Are The Price Projections for the Next Five Years?
Assumptions:
- Steady market share within the narcolepsy indication.
- No significant changes in regulatory or reimbursement policies.
- Introduction of a biosimilar or generic version unlikely within forecast period due to REMS constraints and drug complexity.
| Year |
Estimated Global Sales |
Estimated Price Range (USD) |
Notes |
| 2023 |
$700 million |
$28,000 - $30,000 |
Current market remains stable. |
| 2024 |
$720 million |
$27,000 - $31,000 |
Slight increase due to market expansion in Europe. |
| 2025 |
$735 million |
$26,000 - $32,000 |
New patient initiation in select European countries. |
| 2026 |
$750 million |
$26,000 - $33,000 |
Continued expansion; no biosimilars available. |
| 2027 |
$765 million |
$25,000 - $34,000 |
Price adjustments influenced by inflation and competitive dynamics. |
Key Factors Influencing Projections:
- Market penetration: Limited due to REMS and abuse potential.
- Regulatory environment: No major policy shifts expected that would lower barriers or introduce biosimilars.
- Treatment adoption: Growth depends on increased diagnosis and physician familiarity.
How Do These Projections Compare Globally?
Global sales are expected to mirror U.S. trends with regional variations:
-
Europe: Moderate growth due to expanding awareness and approval in select countries; pricing remains higher with less discounting.
-
Asia: Emerging markets present opportunities, but pricing and reimbursement are less predictable.
What Are The Potential Risks to Price Stability?
- Regulatory changes: Loosening REMS controls could increase access or competition.
- Generic entry: Unlikely within the forecast period, but any development could significantly impact pricing.
- Market saturation: Increased use of alternative treatments or natural remedies might reduce growth.
Key Takeaways
- NDC 70010-0668 (Xyrem) maintains a high-value niche in narcolepsy treatment.
- The global market is approximately $700 million, with steady growth expected over five years.
- Prices range from $25,000 to $34,000 annually, influenced by regional healthcare policies.
- RESTRICTED distribution due to REMS limits market size and competitive pressure.
- Biosimilar or generic competition is unlikely before 2028, supporting price stability.
FAQs
1. What are the main indications for NDC 70010-0668?
Treatment of narcolepsy with cataplexy or hypocretin deficiency.
2. Are biosimilars likely for this drug?
Unlikely within the next five years due to complex formulation and REMS restrictions.
3. How does pricing vary internationally?
European prices tend to be slightly lower than U.S. prices due to different reimbursement policies, but overall range remains $15,000-$25,000 annually.
4. What factors could lead to price decreases?
Introduction of generic or biosimilar competitors, regulatory relaxation, or market saturation.
5. Is future growth dependent on new indications?
Current evidence suggests limited potential beyond narcolepsy and cataplexy; growth primarily relies on prescription expansion within these indications.
Citations:
- IQVIA. "Global Oncology & Specialty Drug Sales Data," 2022.
- National Sleep Foundation. "Narcolepsy Facts & Figures," 2021.
- FDA. "Xyrem (sodium oxybate) prescribing information," 2002.
- Xyrem REMS Program. FDA.
